
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific's total sales for the fourth quarter reached $4.561 billion, reflecting a robust year-over-year growth of 19.5%, significantly exceeding projections. The Cardiovascular business showed particularly strong performance with a year-over-year increase of 27%, contributing 65% of fourth-quarter sales, thus highlighting the substantial demand for the company's diverse portfolio of less invasive medical devices. Furthermore, the positive outlook is bolstered by expectations of continued operating margin expansion, driven by higher gross margins, strategic reinvestment in R&D, and the potential for greater operating leverage from faster revenue growth.
Bears say
The financial outlook for Boston Scientific indicates challenges ahead, with a projected decline in gross margins for 2024 by approximately 40 basis points year-over-year, primarily due to limitations from the capital sale energy generator system. Additionally, potential risks encompass weaker-than-expected sales in key segments such as electrophysiology and structural heart, alongside increased competition and operating margin contraction that could hinder revenue growth. The company's revenue projections suggest flat growth in the first quarter of 2025, reflecting significant headwinds including market share losses and regulatory hurdles, which contribute to the negative outlook on its stock.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares